Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles-Reference-Cited by-同舟云学术

Comparison of safety outcomes of anticancer drugs in Japanese and non-Japanese patients in multi-regional clinical trials: meta-analysis of safety profiles

Published:2023-05-10 Issue:3 Volume:41 Page:483-492
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Tamai Toshiyuki^ORCID,Narukawa Mamoru

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-023-01362-7.pdf

Reference15 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492

2. Paoletti X, Ezzalfani M, Le Tourneau C (2015) Statistical controversies in clinical research: Requiem for the 3 + 3 design for phase I trials. Ann Oncol 26:1808–1812. https://doi.org/10.1093/annonc/mdv266

3. Jänne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE (2016) Dose finding of small-molecule oncology drugs: optimization throughout the development life cycle. Clin Cancer Res 22:2613–2617. https://doi.org/10.1158/1078-0432.CCR-15-2643

4. Verheul HMW, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7:475–485. https://doi.org/10.1038/nrc2152

5. Hsiehchen D, Espinoza M, Hsieh A (2015) The cooperative landscape of multinational clinical trials. PLoS One 10:e0130930. https://doi.org/10.1371/journal.pone.0130930

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the Incidence of Adverse Events Between Japanese and Non-Japanese Healthy Subjects in Phase I Studies: A Systematic Review and Meta-Analysis;Clinical Drug Investigation;2023-12-02